The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

NPJ Breast Cancer · 2024 · PMC11187074 · PMID 38898072

Europe PMC DOI

hedged sentence

0.0070

closest p · 0.1× alpha

0.0070

boldest claim

The sentences

highly significantP = 0.007actually significant

The overall test on treatment effect was insignificant for T1a patients ( P = 0.906) but highly significant for T1b/T1c patients ( P = 0.007).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.